New Clinical Developments in Histone Deacetylase Inhibitors for Epigenetic Therapy of Cancer

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2009 Jun 3

PMID 19486511

Citations 36

Authors

Shundong Cang

Yuehua Ma

Delong Liu

Affiliations

Soon will be listed here.

Abstract

DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.

Citing Articles

Acetyl-CoA Carboxylase Inhibitor CP640.186 Increases Tubulin Acetylation and Impairs Thrombin-Induced Platelet Aggregation.

Octave M, Pirotton L, Ginion A, Robaux V, Lepropre S, Ambroise J Int J Mol Sci. 2021; 22(23).

PMID: 34884932 PMC: 8658010. DOI: 10.3390/ijms222313129.

Cancer's epigenetic drugs: where are they in the cancer medicines?.

Ghasemi S Pharmacogenomics J. 2019; 20(3):367-379.

PMID: 31819161 DOI: 10.1038/s41397-019-0138-5.

Emerging roles of Myc in stem cell biology and novel tumor therapies.

Yoshida G J Exp Clin Cancer Res. 2018; 37(1):173.

PMID: 30053872 PMC: 6062976. DOI: 10.1186/s13046-018-0835-y.

Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.

Messaoudi K, Ali A, Ishaq R, Palazzo A, Sliwa D, Bluteau O Nat Commun. 2017; 8(1):1786.

PMID: 29176689 PMC: 5702605. DOI: 10.1038/s41467-017-01690-2.

Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.

Yoshida G J Hematol Oncol. 2017; 10(1):67.

PMID: 28279189 PMC: 5345270. DOI: 10.1186/s13045-017-0436-9.

References

Blumenschein Jr G, Kies M, Papadimitrakopoulou V, Lu C, Kumar A, Ricker J . Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2007; 26(1):81-7. DOI: 10.1007/s10637-007-9075-2. View

Marks P . Discovery and development of SAHA as an anticancer agent. Oncogene. 2007; 26(9):1351-6. DOI: 10.1038/sj.onc.1210204. View

Carducci M, Gilbert J, Bowling M, Noe D, Eisenberger M, Sinibaldi V . A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001; 7(10):3047-55. View

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

Kelly W, Marks P . Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005; 2(3):150-7. DOI: 10.1038/ncponc0106. View

Lu L, Liu D, Ma X, Beklemishev A, Seiter K, Ahmed T . The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep. 2006; 16(6):1363-7. View

Hurtubise A, Momparler R . Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006; 58(5):618-25. DOI: 10.1007/s00280-006-0225-6. View

Silverman L, Demakos E, Peterson B, Kornblith A, Holland J, Odchimar-Reissig R . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-40. DOI: 10.1200/JCO.2002.04.117. View

Keen J, Yan L, Mack K, Pettit C, Smith D, Sharma D . A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003; 81(3):177-86. DOI: 10.1023/A:1026146524737. View

10.

Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S . Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp. 2004; 259:249-66. View

11.

Raj K, John A, Ho A, Chronis C, Khan S, Samuel J . CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007; 21(9):1937-44. DOI: 10.1038/sj.leu.2404796. View

12.

Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M . Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005; 4(1):22. PMC: 1198251. DOI: 10.1186/1476-4598-4-22. View

13.

Undevia S, Kindler H, Janisch L, Olson S, Schilsky R, Vogelzang N . A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004; 15(11):1705-11. DOI: 10.1093/annonc/mdh438. View

14.

Cang S, Lu Q, Ma Y, Liu D . Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets. 2010; 10(5):539-45. DOI: 10.2174/156800910791517217. View

15.

Sung M, Waxman S . Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res. 2007; 27(2):995-1001. View

16.

Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F . Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem. 2008; 51(14):4072-5. DOI: 10.1021/jm800251w. View

17.

Shapiro T, Fahey J, Dinkova-Kostova A, Holtzclaw W, Stephenson K, Wade K . Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer. 2006; 55(1):53-62. DOI: 10.1207/s15327914nc5501_7. View

18.

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F . A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006; 12(15):4628-35. DOI: 10.1158/1078-0432.CCR-06-0511. View

19.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda W . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2007; 111(3):1060-6. DOI: 10.1182/blood-2007-06-098061. View

20.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View